Clinical Trial Update: Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 tolerability study of Trichostatin A in subjects with relapsed or refractory hematologic malignancies is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• Trichostatin A (trichostatin A)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Relapsed or Refractory Hematologic Malignancies | Phase 1 | Status: RECRUITING